Lead Product(s) : Dacomitinib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Penn Study Uncovers Possible COVID-19 Drugs — Including Several That are Already FDA-Approved
Details : Of the nine drugs found to reduce SARS-CoV-2 replication in respiratory cells, three already have FDA approval: the transplant-rejection drug cyclosporine, the cancer drug dacomitinib, and the antibiotic salinomycin.
Product Name : Vizimpro
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 04, 2021
Lead Product(s) : Dacomitinib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
